ALCLS Share Price

Open 16.49 Change Price %
High 17.20 1 Day -0.10 -0.61
Low 16.15 1 Week -0.21 -1.27
Close 16.29 1 Month 1.34 8.96
Volume 138365 1 Year -10.22 -38.55
52 Week High 30.14
52 Week Low 14.08
ALCLS Important Levels
Resistance 2 17.26
Resistance 1 16.86
Pivot 16.55
Support 1 15.72
Support 2 15.32
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
DPT 0.26 100.00%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
CS 24.30 3.67%
More..
EPA France Top Gainers Stocks
DPT 0.26 100.00%
MLERO 0.34 25.93%
ALADO 0.05 25.00%
EMG 6.95 19.62%
EMG 6.95 19.62%
EMG 6.95 19.62%
EMG 6.95 19.62%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
More..
EPA France Top Losers Stocks
ALDV 0.11 -15.38%
MLMGL 5.86 -9.85%
MLCMB 132.02 -8.94%
SFCA 2.09 -8.73%
SEC 0.59 -6.35%
SEC 0.59 -6.35%
ALINN 23.00 -6.08%
MLVIS 0.95 -5.94%
PGP 77.50 -5.83%
PGP 77.50 -5.83%
More..

Cellectis SA (EPA: ALCLS)

ALCLS Technical Analysis 5
As on 7th Dec 2016 ALCLS Share Price closed @ 16.29 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 22.33 & Strong Sell for SHORT-TERM with Stoploss of 18.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALCLS Target for December
1st Target up-side 19.6
2nd Target up-side 21.77
3rd Target up-side 23.94
1st Target down-side 13.4
2nd Target down-side 11.23
3rd Target down-side 9.06
ALCLS Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cellectis.com
ALCLS Address
ALCLS
8 rue de la Croix Jarry
Paris, 75013
France
Phone: 33 1 81 69 16 00
Interactive Technical Analysis Chart Cellectis SA ( ALCLS EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cellectis SA
ALCLS Business Profile
Cellectis, together with its subsidiaries, operates as a genome engineering company in France and internationally. The company designs and markets meganucleases and TALENs, which are tools that enable targeted modifications to DNA in the research, biomanufacturing, agro biotechnology, and therapeutic sectors; and develops and markets genome customization products used to create stable and isogenic cell lines with various characteristics and performances for use in the drug development, gene function studies, and protein production sectors. It also develops nucleases for various therapeutic applications, including correction of a genetic defect in the patient’s genome; destruction of viral genomes; or inactivation of genes to create cells with modified characteristics in the fields of cancer, viral infections, and genetic diseases. In addition, the company focuses on plant genome modification using nucleases that recognize specific DNA sequences to develop species with traits of value; and development of stem cell technology for controlling stem cell production and differentiation. It has strategic partnership agreement with Les Laboratoires Servier to develop and commercialize product candidates targeting leukemia and solid tumors. Cellectis was founded in 1999 and is based in Paris, France.